Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.
Journal: Transplantation and cellular therapy
Published: July 27, 2025
Expanded antigen-specific donor regulatory T cells for GVHD prevention.
Journal: Blood
Published: July 02, 2025
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.
Journal: Bone marrow transplantation
Published: April 03, 2025
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Journal: NEJM evidence
Published: February 25, 2025
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant.
Journal: American journal of hematology
Published: January 24, 2025
A Randomized Clinical Trial Evaluating Lactiplantibacillus Plantarum for the Prevention of GI aGvHD: A Report From the Children's Oncology Group (ACCL1633).
Journal: Transplantation and cellular therapy
Published: January 08, 2025
Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients.
Journal: Cancers
Published: November 04, 2024
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation.
Journal: Open forum infectious diseases
Published: August 07, 2024
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Journal: Transplantation and cellular therapy
Published: June 09, 2024
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide.
Journal: Transplantation and cellular therapy
Published: June 09, 2024
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations.
Journal: American journal of hematology
Published: February 14, 2024
Last Updated: 09/26/2026